Sentences with phrase «effects of your treatment program»

Not exact matches

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tPrograms (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Cold Logic can address the effect of oil fouling in refrigeration systems operating chillers, freezers and plate freezers through the use of a refrigerant side treatment program.

HIV Medicine DOI: 10.1111/j.1468-1293.2011.00918.x IBFAN - Asia Position Statement on HIV and Infant Feeding, 13 October 2008 South African Tshwane Declaration on breastfeeding, S Afr J Clin Nutr 2011; 24 (4) UNAIDS 2010, Strategy Getting to Zero, UNAIDS Strategy 2011 — 2015 UNAIDS 2010, Agenda for Accelerated Country Action for Women, Girls, Gender Equality and HIV, 2010 - 2014 UNAIDS 2011, Countdown to Zero: Global plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive, 2011 - 2015 UNAIDS 2011 Press Release, 9 June, World leaders launch plan to eliminate new HIV infections among children by 2015 UNICEF Convention on the Rights of the Child UNICEF 2010, Facts for Life UNICEF 2011, Programming Guide, Infant and Young Child Feeding, 26 May 2011 WHO / UNICEF 2003, Global strategy for infant and young child feeding WHO 2007, Evidence on the long - term effects of breastfeeding: systematic reviews and meta - analysis WHO, UNAIDS, UNICEF 2009, Towards universal access: scaling up priority HIV / AIDS interventions in the health sector: progress report 2009 WHO 2009, Women and health, Today's evidence tomorrow's agenda WHO 2009, Acceptable medical reasons for use of breast - milk substitutes WHO 2009, Rapid advice: use of antiretroviral drugs for treating pregnant womenand preventing HIV Infection in infants WHO 2009, Rapid advice: revised WHO principles and recommendations on infant feeding in the context of HIV WHO 2010, Priority Interventions — HIV / AIDS prevention, treatment and care in the health sector WHO 2010, Guidelines on HIV and infant feeding: Principles and recomendations for infant feeding in the context of HIV and a summary of evidence WHO 2010, Annexure 7b to Guidelines on HIV and infant feeding.

Meta - analyses of studies evaluating these programs show positive effects on the competence, efficacy and psychological health of the parents, as well as on the behaviour of the children.49, 50 A recent implementation study of a strategy for parenting and family support showed that families in the treatment group had far fewer cases of substantiated child maltreatment, abuse injuries and out - of - home placements.51

«A significant body of research has resulted in a shift from thinking of placebos as just «dummy» treatments to recognizing that placebo effects encompass numerous aspects of the health care experience and are central to medicine and patient care,» said the article's coauthor Ted Kaptchuk, Director of the Program in Placebo Studies at Beth Israel Deaconess Medical Center (BIDMC) and Professor of Medicine at Harvard Medical School.

U.S. Health & Human Services Secretary Sylvia Burwell last year proposed a response, calling for a program to change doctors» opioid prescribing practices, to expand the use of naloxone, a drug used to reverse the effects of an opioid overdoses, and increase patient access to medication assisted treatments for opioid use disorders.

Instead, researchers told the European Breast Cancer Conference that their findings suggest that extending screening programs to older women results in a large proportion of women being over-treated, and at risk from the harmful effects of such treatment, because these women were more likely to die from other causes than from any tumors detected in the early stages of growth.

The Decision Counseling Program © developed by Dr. Myers and colleagues differs from previous decision aids in that a nurse educator uses the program not only to provide information about options, but also to identify and weigh the importance of things that matter to the patient (e.g., worry about treatment side effects, concern about developing aggressive cProgram © developed by Dr. Myers and colleagues differs from previous decision aids in that a nurse educator uses the program not only to provide information about options, but also to identify and weigh the importance of things that matter to the patient (e.g., worry about treatment side effects, concern about developing aggressive cprogram not only to provide information about options, but also to identify and weigh the importance of things that matter to the patient (e.g., worry about treatment side effects, concern about developing aggressive cancer).

Other projects include an analysis of regional variations of cancer treatment in Texas, a study of the effect of smoking bans on hospitalization rates, and a study of whether shared savings programs for physicians can reduce overall patient health care expenditures.

«There's a great need in cancer patients to be able to quickly and easily assess if a particular treatment is working in order to switch to another if it's not, thus avoiding wasted time, potential side effects and cost,» says Kala Visvanathan, M.D., M.H.S., professor of epidemiology at the Johns Hopkins Bloomberg School of Public Health, professor of oncology at the Johns Hopkins University School of Medicine and director of the Clinical Cancer Genetics Program at the Johns Hopkins Kimmel Cancer Center.

The implications of these data are that maternal treatment with antioxidants may provide possible therapy against the programming effects on vascular dysfunction in pregnancy complicated by fetal hypoxia, such as during placental insufficiency, preeclampsia, gestational diabetes or high altitude pregnancy.

examines long - term sequelae resulting from a diagnosis of childhood cancer and its treatment, and health care relating to these late effects.This multi-study initiative is funded by a Canadian Cancer Society program project grant, with additional funding from CCS BC and Yukon Division, and has examined long - term health effects and educational attainment, health care utilization, and quality of follow - up care among disease survivors.

This is in accordance with previous reports that decitabine and 5 - azacytidine produce a marked synergistic effect in combination with suberoylanilide hydroxamic acid and romidepsin in T - lymphoma cell lines by modulating cell cycle arrest and apoptosis.26, 27 As a mechanism of action, KMT2D mutations of B - lymphoma cells promote malignant outgrowth by perturbing methylation of H3K4 that affect the JAK - STAT, Toll - like receptor, or B - cell receptor pathway.28, 29 Here our study indicated that dual treatment with chidamide and decitabine enhanced the interaction of KMT2D with the transcription factor PU.1, thereby inactivating the H3K4me - associated signaling pathway MAPK, which is constitutively activated in T - cell lymphoma.13, 30,31 The transcription factor PU.1 is involved in the development of all hematopoietic lineages32 and regulates lymphoid cell growth and transformation.33 Aberrant PU.1 expression promotes acute myeloid leukemia and is related to the pathogenesis of multiple myeloma via the MAPK pathway.34, 35 On the other hand, PU.1 is also shown to interact with chromatin remodeler and DNA methyltransferease to control hematopoiesis and suppress leukemia.36 Our data thus suggested that the combined action of chidamide and decitabine may interfere with the differentiation and / or viability of PTCL - NOS through a PU.1 - dependent gene expression program.

Research in the Leukemia Program spans from direction of clinical trials to basic molecular studies of leukemia biology, immunotherapy and development of novel agents, and to mitigating the late effects of treatment in long - term survivors.

Replacing the chemotherapy with a safe, side - effect - free treatment would mean that the established programs for immune system restoration could immediately expand to become a useful, effective treatment for immunosenescence, the age - related failure of the immune system.

November 5, 2015 Richard L. Landau, MD, 1916 - 2015 For more than half a century, Richard L. Landau was a demanding professor of medicine, performing path - breaking research into the effects of human hormones and treatment of hormone - related diseases while building a world - renowned endocrinology program at the University of Chicago.

This is a 1st step on the way to vindicating the positive effects of programs like the Blue Gym and Green Gym, as well as innovative interventions by practitioners which include outdoor exercising as part of holistic treatments for those experiencing depression and similar mental conditions.

Some important studies include: • Beneficial effects of a high carbohydrate, high fiber diet on hyperglycemic diabetic men (1976) • Response of non-insulin-dependent diabetic patients to an intensive program of diet and exercise (1982) • Diet and exercise in the treatment of NIDDM: The need for early emphasis (1994) • Toward improved management of NIDDM: A randomized, controlled, pilot intervention using a low fat, vegetarian diet (1999) • The effects of a low - fat, plant - based dietary intervention on body weight, metabolism, and insulin sensitivity (2005) • A low - fat vegan diet improves glycemic control and cardiovascular risk factors in a randomized clinical trial in individuals with type 2 diabetes (2006) • A low - fat vegan diet and a conventional diabetes diet in the treatment of type 2 diabetes: a randomized, controlled, 74 - wk clinical trial (2009) • Vegetarian diet improves insulin resistance and oxidative stress markers more than conventional diet in subjects with Type 2 diabetes (2011) • Glycemic and cardiovascular parameters improved in type 2 diabetes with the high nutrient density (HND) diet (2012)

Past and current research projects have explored the effect of a diagnosis of breast cancer on lifestyle and mental health and adherence to lifestyle - based (i.e. nutrition and exercise) and drug therapy treatment programs.

1935 Effects of the high carbohydrate - low calorie diet upon carbohydrate tolerance in diabetes mellitus 1955 Low - fat diet and therapeutic doses of insulin in diabetes mellitus 1958 Effect of rice diet on diabetes mellitus associated with vascular disease 1976 Beneficial effects of a high carbohydrate, high fiber diet on hyperglycemic diabetic men 1977 Effect of carbohydrate restriction and high carbohydrates diets on men with chemical diabetes 1979 High - carbohydrate, high - fiber diets for insulin - treated men with diabetes mellitus 1981 High carbohydrate high in fibre diet in diabetes 1982 Response of non-insulin-dependent diabetic patients to an intensive program of diet and exercise 1983 Long - term use of a high - complex - carbohydrate, high - fiber, low - fat diet and exercise in the treatment of NIDDM patients 1994 Diet and exercise in the treatment of NIDDM: the need for early emphasis 1999 Toward improved management of NIDDM: A randomized, controlled, pilot intervention using a lowfat, vegetarian diet 2005 The effects of a low - fat, plant - based dietary intervention on body weight, metabolism, and insulin sensitivity 2006 A low - fat vegan diet improves glycemic control and cardiovascular risk factors in a randomized clinical trial in individuals with type 2 diabetes 2006 Effect of short ‐ term Pritikin diet therapy on the metabolic syndrome 2009 A low - fat vegan diet and a conventional diabetes diet in the treatment of type 2 diabetes: a randomized, controlled, 74 - wk clinical trial

If one's purpose is to evaluate the effects of a specific public policy, such as the District of Columbia Opportunity Scholarship Program (OSP), then the comparison of the average outcomes of the treatment and control groups, regardless of what proportion attended which types of school, is most appropriate.

Specifically, he will work with the PI and core project staff to develop an analysis plan, direct the evaluation of the efficacy of the Core Knowledge Language Arts Listening and Learning Read Aloud Program, articulate the fully specified multi-level models used to estimate treatment impacts on child - level vocabulary, listening comprehension and domain knowledge outcomes, and guide the secondary analyses that examine whether the quality of read alouds mediate treatment effects on child outcomes and the baseline, child - level moderators of treatment effects.

There have been ten analyses of random - assignment voucher program experiments (random - assignment being the gold - standard of testing treatment effects).

Researchers often summarize the impact of programs and practices in terms of an effect size that measures the difference between the treatment and control groups.

Assessing program effects in the presence of treatment - baseline interactions: a latent curve approach.

Correlation across HS programs of effect of treatment on child cognitive scores (xaxis) and effect of treatment on parent involvement (y - axis)

In effect, the treatment group consists of only those students who complete a year of preschool, and we would expect their scores to be higher (adjusting for age) than a control group that includes everyone who starts the pre-K program.

The guidelines that are based on understanding dementia and effects of music therapy are commonly used to design hypothetical programs in the treatment of Alzheimer and dementia Continue reading

In this program, you will acquire knowledge about mood disorders, causes, symptoms and treatment options, fostering positive prevention strategies, treatment and recovery strategies for depression, anxiety, addiction and stress, reducing stigmatizing behaviours, attitudes and effects, and offering support and resources for recovery and the maintenance of wellness.

This program provides knowledge about mood disorders, causes, symptoms and treatment options, fostering positive prevention strategies, treatment and recovery strategies for depression, anxiety, addiction and stress, reducing stigmatizing behaviours, attitudes and effects, and offering support and resources for recovery and the maintenance of wellness.

Effects were more consistent on physical abuse, however, with mothers in the treatment group reporting fewer instances of very serious physical abuse at one year and fewer instances of serious abuse at two years.54 In Alaska, the HFA program was associated with less psychological aggression, but it had no effects for neglect or severe abusive behaviors.55 Similarly, in the San Diego evaluation of HFA, home - visited mothers reported less use of psychological aggression at twenty - four and thirty - six months.56 Early Start also reported small effects in terms of lowering rates of severe physical abuse.57

As a family therapist and former clinical director of adolescent treatment programs, her concern for the adverse effects of stress on the social and emotional development of teens led to pioneering work in the area of self - compassion for teens.

Participants were drawn from a larger study examining (i) the effects of trauma on children over time and (ii) the efficacy of the SAFE Homes intervention, a DCF program in which children who have been removed from their parents» care are placed temporarily in state - run facilities rather than immediate foster care to facilitate assessment and treatment planning.

In the Infant Health and Development program, mothers in the intervention group engaged in higher - quality interactions with their infants, though the effects were small.82 In New Zealand, Early Start documented higher positive parenting attitudes, a greater prevalence of nonpunitive attitudes, and more favorable overall parenting scores for families in the treatment group.83 In Queensland, mothers in the intervention group were rated as significantly higher in emotional and verbal responsivity.84

Although most outcomes were reviewed at program completion to observe the effects of a high - intensity comprehensive treatment program for low - birth - weight infants, 39 certain outcomes were examined after the first year and provide a test of the home - visiting component on its own.40

Finally, Stahmer and Gist27 examined the effects of a parent education support group with a parent education program that focused on pivotal response training, a treatment program designed to enhance core skill areas in autism by using naturalistic interactions.

Indeed, the difference in surveillance between the treatment and control groups probably explains why so few home - visiting programs have measurable effects on rates of abuse and neglect.

One evaluation conducted in Queensland, Australia, reported moderate reductions in depressive symptoms for mothers in the intervention group at the six - week follow - up.89 A subsequent follow - up, however, suggested that these benefits were not long lasting, as the depression effects had diminished by one year.90 Similarly, Healthy Families San Diego identified reductions in depression symptoms among program mothers during the first two years, but these effects, too, had diminished by year three.91 In Healthy Families New York, mothers at one site (that was supervised by a clinical psychologist) had lower rates of depression at one year (23 percent treatment vs. 38 percent controls).92 The Infant Health and Development program also demonstrated decreases in depressive symptoms after one year of home visiting, as well as at the conclusion of the program at three years.93 Among Early Head Start families, maternal depressive symptoms remained stable for the program group during the study and immediately after it ended, but decreased just before their children entered kindergarten.94 No program effects were found for maternal depression in the Nurse - Family Partnership, Hawaii Healthy Start, Healthy Families Alaska, or Early Start programs.

Indeed, Jay Belsky incorporated all of these risk factors into his process model of parenting, 11 and data from multiple studies support links to child well - being.12 In an experiment on the effectiveness of a program for low - birth - weight infants, Lawrence Berger and Jeanne Brooks - Gunn examined the relative effect of both socioeconomic status and parenting on child abuse and neglect (as measured by ratings of health providers who saw children in the treatment and control groups six times over the first three years of life, not by review of administrative data) and found that both factors contributed significantly and uniquely to the likelihood that a family was perceived to engage in some form of child maltreatment.13 The link between parenting behaviors and child maltreatment suggests that interventions that promote positive parenting behaviors would also contribute to lower rates of child maltreatment among families served.

Of those that examined immunizations (NFP - Memphis, HFA, HSP, EHS, Queensland, and Early Start), only EHS identified a significant program effect on immunizations, though the size of the effect was quite small and applied to the comparison of the entire treatment group to controls, not specifically to those families who had received home visits.70 The one - year follow - up of the Queensland program also suggested a trend in favor of the intervention group's having higher levels of vaccinations than the control group.Of those that examined immunizations (NFP - Memphis, HFA, HSP, EHS, Queensland, and Early Start), only EHS identified a significant program effect on immunizations, though the size of the effect was quite small and applied to the comparison of the entire treatment group to controls, not specifically to those families who had received home visits.70 The one - year follow - up of the Queensland program also suggested a trend in favor of the intervention group's having higher levels of vaccinations than the control group.of the effect was quite small and applied to the comparison of the entire treatment group to controls, not specifically to those families who had received home visits.70 The one - year follow - up of the Queensland program also suggested a trend in favor of the intervention group's having higher levels of vaccinations than the control group.of the entire treatment group to controls, not specifically to those families who had received home visits.70 The one - year follow - up of the Queensland program also suggested a trend in favor of the intervention group's having higher levels of vaccinations than the control group.of the Queensland program also suggested a trend in favor of the intervention group's having higher levels of vaccinations than the control group.of the intervention group's having higher levels of vaccinations than the control group.of vaccinations than the control group.71

However, for both child abuse and parent stress, the average effect sizes were not different from zero, suggesting a lack of evidence for effects in these areas.108 Earlier meta - analytic reviews have also noted the lack of sizable effects in preventing child maltreatment — again citing the different intensity of surveillance of families in the treatment versus control groups as an explanation (though the authors did report that home visiting was associated with an approximately 25 percent reduction in the rate of childhood injuries).109 Another review focusing on the quality of the home environment also found evidence for a significant overall effect of home - visiting programs.110 More recently, Harriet MacMillan and colleagues published a review of interventions to prevent child maltreatment, and identified the Nurse - Family Partnership and Early Start programs as the most effective with regard to preventing maltreatment and childhood injuries.

The program of prenatal and infancy home visiting by nurses, tested with a primarily white sample, produced a 48 percent treatment - control difference in the overall rates of substantiated rates of child abuse and neglect (irrespective of risk) and an 80 percent difference for families in which the mothers were low - income and unmarried at registration.21 Corresponding rates of child maltreatment were too low to serve as a viable outcome in a subsequent trial of the program in a large sample of urban African - Americans, 20 but program effects on children's health - care encounters for serious injuries and ingestions at child age 2 and reductions in childhood mortality from preventable causes at child age 9 were consistent with the prevention of abuse and neglect.20, 22

Where program effects were moderated by the child's sex in a coherent way, we have noted this in the presentation of the findings, in which case the model includes SES as a covariate rather than a classification factor and includes all interactions among treatment, marital status, and sex.

Behavioral assessment of psychostimulant effects on ADD children in a summer day treatment program.

Identifies seven studies and applies meta - analysis technique to examine, compare, and synthesize the effects of caregivers» engagement and retention in substance abuse treatment programs.

Meta - Analysis of Substance Abuse Treatment Intervention on Child Welfare Outcomes (PDF - 1,002 KB) Zhang, Huang, & Liu (2014) Identifies seven studies and applies meta - analysis technique to examine, compare, and synthesize the effects of caregivers» engagement and retention in substance abuse treatment Treatment Intervention on Child Welfare Outcomes (PDF - 1,002 KB) Zhang, Huang, & Liu (2014) Identifies seven studies and applies meta - analysis technique to examine, compare, and synthesize the effects of caregivers» engagement and retention in substance abuse treatment treatment programs.

Preventive interventions often find that treatment effects for certain outcomes vary across subgroups of study participants.11, 12 In this study, we examine how domestic violence limits the effectiveness of the home - visitation program in preventing maltreatment.

In addition, many of the early intervention programs that have been shown to have positive treatment effects are resource intensive and target high - risk families, on the basis of socioeconomic status, childhood disabilities, parental substance use, or child maltreatment.1

Evaluations of sustained treatment effects for other, more - intensive, early childhood interventions have yielded mixed results, with variation being attributed to unevenness in both program quality and evaluation rigor.10, 11 Less - intensive interventions, such as the Comprehensive Child Development Program, have reported no effect during or after the intervention.12 Intensive interventions with short - term effects seem to be more likely to demonstrate sustained benefits for children's cognitive and social development and parenting behavprogram quality and evaluation rigor.10, 11 Less - intensive interventions, such as the Comprehensive Child Development Program, have reported no effect during or after the intervention.12 Intensive interventions with short - term effects seem to be more likely to demonstrate sustained benefits for children's cognitive and social development and parenting behavProgram, have reported no effect during or after the intervention.12 Intensive interventions with short - term effects seem to be more likely to demonstrate sustained benefits for children's cognitive and social development and parenting behaviors.11

The absence of program effect with the official arrest data may be explained by a significant, 9-fold higher rate of official arrest records prior to randomization (0.44 vs 0.05) found for treatment group 4 mothers who were unmarried and of low SES and whose children remained in Chemung County compared with their treatment group 1 and 2 counterparts.